21:15 , Mar 5, 2019 |  BC Innovations  |  Distillery Techniques

Vascularized kidney organoids for modeling renal disease

TECHNIQUES CATEGORY: Disease models TECHNOLOGY: 3-D models Vascularized kidney organoids could be used to study kidney development and model renal diseases. The organoids are generated in three steps: culturing human pluripotent stem cells with fibroblast...
23:59 , Dec 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer; colorectal cancer; lung cancer Cell culture and mouse studies suggest inhibiting GSK3 could help treat KRAS-driven pancreatic, colon and lung cancers. Screening of a library of 304 kinase inhibitors in cell-based growth...
04:47 , Nov 9, 2018 |  BC Innovations  |  Tools & Techniques

HitGen’s DNA for small molecules

With more than 60 partnerships under its belt, HitGen Ltd. has become a major gateway for companies to access DNA-encoded library technology -- a high efficiency form of combinatorial chemistry that upstages high throughput screening....
18:38 , Oct 18, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Spinal cord injury (SCI) Rat studies suggest human embryonic stem cell (hESC)-derived spinal cord neural stem cells (NSCs) could help treat SCI. hESCs were cultured with fibroblast growth factors and inhibitors of bone morphogenic...
15:47 , Aug 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) In vitro and cell culture studies identified two thiazolidinedione-based dual inhibitors of tau-aggregation and GSK3B that could help treat AD. Chemical synthesis and in vitro testing in enzymatic activity assays of...
17:56 , May 16, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Rett syndrome Patient sample and mouse studies suggest inhibiting GSK3B could help treat Rett syndrome. In postmortem cerebellum tissue samples from Rett syndrome patients, levels of GSK3B were higher than in samples from unaffected...
21:13 , Apr 17, 2018 |  BC Innovations  |  Distillery Techniques

Disease models; drug properties

TECHNOLOGY: 3-D models; pharmacokinetics/pharmacodynamics 3-D human intestinal organoids could be used to test the PK properties of drug compounds. The organoids are generated by culturing human induced pluripotent stem (iPS) cells in a medium containing...
13:32 , Apr 13, 2018 |  BC Week In Review  |  Clinical News

Fate reports Phase I data for Fate-NK100 in ovarian cancer

Fate Therapeutics Inc. (NASDAQ:FATE) reported data from two evaluable patients with ovarian cancer in the Phase I APOLLO trial showing that Fate-NK100 led to stable disease with evidence of tumor reduction at day 28 in...
22:36 , Apr 4, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: March 2018

New Therapeutic Targets and Biomarkers: March 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during March 2018. Therapeutic targets are defined as any protein, gene or other...
17:46 , Mar 30, 2018 |  BC Week In Review  |  Clinical News

AMO Pharma reports Phase II data for myotonic dystrophy candidate

AMO Pharma Ltd. (Surrey, U.K.) reported data from a Phase II trial in 16 patients ages 13-34 with congenital or childhood-onset myotonic dystrophy type 1 (DM1) showing that tideglusib (AMO-02) was generally well tolerated with...